Conflict of interest:
GC receives fees from Bayer and Elea-Phoenix (Argentina) and participates on the data safety monitoring board or advisory board for Bayer (Larotrectinib).
SLF receives personal fees from Riverboat Study (Research into Visual endpoints and Rb
Health outcomes - 5R01CA225005-03- Salary support), WHO NCD Childhood Cancer – consultant (salary support)-, St Jude Global consultant, St Jude Children’s Research Hospital, Memphis TN, USA, Global Retinoblastoma studies (salary Support).
SLF is also a SLAOP Board member and works at the Retinoblastoma Advisory committee, St Jude Global Alliance, St Jude Children’s Research Hospital.
All other authors declare no competing interests.
Role of funding source : No funding was used for this study
Ethics committee approval: All responses were anonymous and institutional ethical review was not required.